Grow Esoteric Through Disease Focus Jay Wohlgemuth, M.D. Senior Vice President, Science and Innovation the new QUEST

Safe Harbor Disclosure This presentation may contain forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Quantitative and Qualitative Disclosures About Market Risk" in the company's 2011 Annual Report on Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Quantitative and Qualitative Disclosures About Market Risk," and "Risk Factors" in the company's Quarterly Reports on Form 10-Q and other items throughout the Form 10-K and the company's 2012 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. the new QUEST

------------------------------------------------- Business Lines (Breadth) ------------------------------------------------- Cardiovascular & Metabolism ------------------------------------------------- Cancer Diagnostics ------------------------------------------------- Neurology ------------------------------------------------- Toxicology & Prescription Drug Monitoring ------------------------------------------------- Infectious Diseases & Immunology ------------------------------------------------- Women's & Reproductive Health ------------------------------------------------- General Health & Wellness ------------------------------------------------- ------------------------------------------------------------ Value Creation - Growth Area Focus (Depth) ------------------------------------------------------------ o Atherosclerosis o Metabolic disease and Diabetes o Rare endocrinology ------------------------------------------------------------ o Breast cancer o Cancer detection ------------------------------------------------------------ o Developmental disease genetics o Dementia and AD ------------------------------------------------------------ o Prescription Drug Monitoring ------------------------------------------------------------ o Chronic Hepatitis (Hep C and B) ------------------------------------------------------------ o Obstetrics and Gynecology complete offering ------------------------------------------------------------ o Primary care, annual visit offering o Wellness & Prevention (includes employer, consumer, physician, hospital) ------------------------------------------------------------ the new QUEST 3 Restore Growth 3

Value Creation from the Integration of Lab Testing and Clinical Information Integration of Health Information / Value / Investment Phase 1 Individual tests Phase 2 Integration of ordering and results for lab testing Phase 3 Integration of non-lab testing into ordering and results Phase 4 Insight driven services and data analytics o Stage investments to move up the chain over time and capture value along the way o Focus progression toward integration on areas with the highest incremental value of integrated information the new QUEST 3 Restore Growth 4

Providing Holistic Solutions Centered on Guideline Supported Standards of Care ENABLERS Providers Payers Patients Easy to use testing panels defined by professional guidelines Lab ordering, rules and alerts - decision support Integration of imaging results included in guidelines testing Enhanced and integrated reporting Integrated data will enable appropriate new care metric generation Patient facing applications enabling compliance and consumerism in medicine the new QUEST 3 Restore Growth 5

Value from Combining Routine, Guideline Mandated Testing with Esoteric Solutions Guidelines Supported Testing Routine Often Primary Care Dementia Dementia Testing - PCP Hepatitis C HCV screening and routine workup Metabolic and Cardiac Disease Metabolic syndrome, diabetes and cardiovascular risk testing Breast, Colon Cancer Colon and Breast cancer screening and routine workup Women's Health Annual visit, PAP, HPV, routine visit Risk Detection Advanced Diagnostics Specialty Care Esoteric Specialist Advanced Alzheimer's evaluation (Athena) HCV treatment selection, monitoring and complications (Focus and Nichols) Diabetes and vascular disease management and complications (Celera/BHL and Nichols) Genomic testing of tissue, sequencing, recurrence detection Fertility, Genetic syndromes, Contraception, Pre-term birth the new QUEST 3 Restore Growth 6

Examples of Combining Routine and Esoteric Testing Guidelines Supported Screening (PCP) Dementia Dementia Testing - PCP 25 million people in U.S. Hepatitis C HCV screening and routine workup 78 million people in U.S. Metabolic and Cardiac Disease Metabolic syndrome, diabetes and cardiovascular risk testing 90 million people in U.S. Esoteric / Advanced Testing (Specialist) Advanced Alzheimer's evaluation (Athena) HCV treatment selection, monitoring and complications (Focus and Nichols) Diabetes and vascular disease management and complications (Celera/BHL and Nichols) the new QUEST 3 Restore Growth 7

Advanced Diagnostic Technology and Expertise Enables our Esoteric Growth Programs Mass Spectrometry: LCMSMS, Other Largest LCMSMS Lab with many important firsts Point of Care Simplexa PCR Influenza FDA approved Other ASR content available Advanced Sequencing 1st Application Released 2012 DNA Combing Differentiation on genetic predisposition testing Novel Molecular Markers: Methylation, miRNA, Microarrays ColoVantage - 1st blood based methylation test in US Proteomics 1st aptamer based clinical diagnostic (EGFR, 2012) Pipeline with aptamers and MS the new QUEST 3 Restore Growth 8

Key Takeaways - Grow Esoteric Through Disease Focus o Focus on delivering holistic solutions responsive to the needs of clinicians and payors - aligned with commercial objectives o We will address a significant near term clinical opportunity to close the "guidelines gap" in care o Investments in technology and new tests will provide esoteric solutions to clinical problems for specialty care building on our past successes and leveraging our strategic acquisitions the new QUEST 3 Restore Growth 9